Summary: The patient is a male aged 62 living in Ibaraki Prefecture. Eight years ago, a rash first appeard on the left side of the lower back during summer. Two years later, the rash had spread to almost the entire body. In 1983, he was diagnosed by the dermatological department of the Mito Kyodo Hospital as having chromomycosis due to Fonsecaea pedrosoi. He received treatment using flucytosine without any significant improvement. Superficial lymph node swellings and multiple subcutaneous nodules appeared in December of 1985. He entered our institute in May of 1987. In addition to a rash, subcutaneous nodules, and lymph node swellings, at that time abnormal shadows were observed in both lungs and the liver. F. pedrosoi was isolated from the rash, subcutaneous nodules and lymph node swellings. F. pedrosoi was also isolated from a fluid obtained by brushing the left lung through a bronchus. The lesion of the right lung was excised. He was pathologically diagnosed as having squamous cell carcinoma. Findings suggesting infection by black fungi were not observed in this lesion and no fungi were isolated from this lesion. Zusammenfassung: Bei einem 62‐jährigen Mann aus der Ibaraki‐ Präfektur zeigte sich vor 8 Jahren im Sommer zum ersten Mal ein Rash auf der linken Seite des unteren Rükkens. Zwei Jahre später hatte sich der Rash fast ganz über den Körper ausgebreitet. 1983 wurde bei ihm in der dermatologischen Abteilung des Mito Kyodo Hospitals eine durch Fonsecaea pedrosoi bedingte Chromomykose diagnostiziert. Er wurde mit Flucytosin behandelt, ohne daß sich sein Zustand signifikant besserte. Im Dezember 1985 machten sich oberflächliche Lymphknotenschwellungen und multiple, subkutane Knoten bemerk‐bar. Er wurde im Mai 1987 in unser Institut aufgenommen. Zusätzlich zum Rash, zu den subkutanen Knoten und den Lymphknoten‐schwellungen wurden zu dieser Zeit abnormale Verschattungen auf beiden Seiten der Lunge und in der Leber gesehen. F. pedrosi wurde vom Rash, aus den subkutanen Knoten und den geschwollenen Lymphknoten isoliert. Außerdem wurde F. pedrosoi aus dem Bürstenabstrich eines Bronchus auf der linken Lungenseite gezüchtet. Die Läsion in der Lunge rechts wurde exzidiert. Die pathologische Untersuchung ergab ein Plattenepithelkarzinom. In dieser Läsion konnten Chromomykose‐Erreger weder mikroskopisch noch kulturell nachgewiesen werden.
The culture medium of a human acute monocytic leukemia cell line (THP-1)was able to induce normal human monocytes to spread. No such ability was found either in the culture medium of a pro myelocyticleukemia cell line (HL-60) nor in that of a diploid human fibroblast cell line (Flow 7000). Gel filtration of the culture medium of THP-1 cells on a size exclusion column (TSKgel G3000SW) revealed that the most obvious monocyte spreading activity was found in the fraction eluted at the position with a molecular weight of about 70,000. This fraction was also able to increase production of angiotensin converting enzyme and Fc receptor sites for IgG on normal human monocytes.
Background: Malignant melanoma, a tumor with reduced radiosensitivity, has been suggested to be overcome by a high-dose fractionation radiotherapy. The proton beam presents physical characteristics that enable such high-dose irradiation. Objective: Our aim is to answer whether or not the proton beam can provide useful treatment for cutaneous melanoma. Methods: Five primary melanomas (4 acral lentiginous and 1 superficial spreading type) and 3 metastatic lymph nodes of 3 different patients were irradiated using the proton beam with a total dose of around 100 Gy fractionated into single doses of approximately 10 Gy. Results: All the macular lesions and a tumor lesion of primary melanoma disappeared completely, and other tumor lesions regressed by 80–90%. The 3 metastatic lymph nodes also regressed by 50–90%. No severe radiation-related complication occurred. Conclusion: Proton radiotherapy may prove to be a useful therapeutic modality for the management of cutaneous malignant melanoma.
Sarcoidosis sera were shown to have higher activity in aggregating normal human monocytes than normal human sera, A kinetic study suggested that monocytes may not be sensitive to the aggregating activity of sarcoidosis serum until they develop to some extent into macrophages. Gel filtration of sarcoidosis sera on Sephadex G-200 showed that the major factor responsible for monocyte aggregation had the molecular weight of about 130,000, This major aggregating factor was unable to increase cell size of normal human monocytes or to increase phagocytosis and glucose consumption of normal human monocytes. It did have the ability to form multinucleate giant cells,
At the Proton Medical Research Center, University of Tsukuba, we performed a pilot study of proton-beam radiotherapy in 12 patients with the following types of carcinoma: Bowen's disease (4), oral verrucous carcinoma (5), and squamous cell carcinoma (3). They received total doses of 51-99.2 Gy in fractions of 2-12.5 Gy. All of the tumours responded well to the treatment. All four lesions of Bowen's disease, three of the five oral verrucous carcinomas, and the three squamous cell carcinomas completely regressed following irradiation. Two squamous cell carcinomas recurred during the follow-up period. One recurrent squamous cell carcinoma was successfully treated by a salvage surgical operation, and in the other case the patient refused further therapy. In two verrucous carcinomas there was 90% regression of tumour volume. No severe radiation-related complication occurred. As proton radiotherapy produces good local tumour control without significant morbidity to the surrounding normal tissues, it may prove to be a useful therapeutic modality for the treatment of skin carcinomas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.